Five pegfilgrastim biosimilars have been added to a newly-created group in France’s list of similar biologics, with Neulasta as the reference brand. At the same time, the country’s ANSM medicines agency has also added further biosimilars to the list against other already-listed biologic brands, and has also created new generic groups for three molecules in its répertoire of generic equivalents.
Five biosimilar versions of pegfilgrastim – Accord’s Pelgraz, Coherus’ Udenyca, Sandoz’ Ziextenzo, Mylan’s Fulphila and Mundipharma’s Pelmeg – have been added to France’s list of similar biologics. All five have been listed against Amgen’s Neulasta as the reference brands for a newly-created similarity group by local medicines agency ANSM.
At the same time, Mylan’s Hulio (adalimumab) and Ogivri (trastuzumab) biosimilars have been added to the list against already-included reference...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
